Patients affected by pulmonary arterial hypertension (PAH) benefit from intensive,
continuous clinical monitoring to guide escalation of treatments that carry the potential to …

Pulmonary arterial hypertension (PAH) is a progressive disease of the lung vascular system,
which leads to right-sided heart failure and ultimately death if untreated. Treatments to …

Hypoxia‐induced excessive pulmonary artery smooth muscle cell (PASMC) proliferation
plays an important role in the pathology of pulmonary arterial hypertension (PAH). Berberine …

Background We conducted a systematic review and network meta-analysis to examine
comparative efficacy and tolerability of pharmacologic interventions for pulmonary arterial …

Pulmonary hypertension (PH) is a frequent complication of left heart disease and
parenchymal lung disease, and it portends increased mortality. A growing number of …

В книге рассмотрены основные положения физиологии системы гемостаза и
диагностики ее нарушений, дана характеристика фармакологических препаратов …

Despite advances in treatments and improved survival, patients with pulmonary
hypertension still experience poor exercise and functional capacity, which has a significant …

Pulmonary arterial hypertension (PAH) is a rare disease that has significant implications with
regard to morbidity and mortality in those affected. With a prevalence of 15 to 60 cases per …

Riociguat is the first approved medication from the novel class of soluble guanylate cyclase
(sGC) stimulators and the only agent approved for treating both chronic thromboembolic …

Rationale Pulmonary hypertension (PH) is associated with significant perioperative
morbidity and mortality. We hypothesised that pulmonary arterial hypertension (PAH) …